Aminocaproic acid (aminocaproic acid) solution for infusions 50 mg/ml. 100 ml. №1 vial

Aminocaproic acid (aminocaproic acid) solution for infusions 50 mg/ml. 100 ml. №1 vial

$8.00

Manufacturer: Ukraine

Antihemorrhagic agents. fibrinolysis inhibitors. ATX code B02A A01.

Surgical operations and pathological processes, accompanied by an increase in fibrinolytic activity of blood and tissues.

To prevent secondary hypofibrinogenemia during massive transfusions of canned blood.

Category:

Description

Ingredients

active ingredient: aminocaproic acid;

100 ml of solution contains aminocaproic acid 5 g;

excipients: sodium chloride, water for injection.

Dosage form

Solution for infusion.

Basic physical and chemical properties : transparent colorless liquid.

Pharmacotherapeutic group

Antihemorrhagic agents. fibrinolysis inhibitors. ATX code B02A A01.

Pharmacodynamics

A solution of Aminocaproic acid 50 mg/ml. acid has a hemostatic, antifibrinolytic effect in bleeding caused by increased fibrinolysis. Its action is associated with the blockade of plasminogen activators and partial inhibition of the influence of plasmin. The drug also inhibits biogenic polypeptides – kinins, contributes to the stabilization of fibrin and its deposition in the vascular bed, induces platelet and erythrocyte aggregation.

Aminocaproic acid has an anti-allergic, antiviral effect, enhances the detoxification function of the liver. The drug inhibits the proteolytic activity associated with the influenza virus. Aminocaproic acid inhibits the early stages of the interaction of the virus with sensitive cells, and also inhibits the proteolytic processing of hemagglutinin. As a result, the functionally active protein of the influenza virus, which ensures its infectious activity, is not formed, and the amount of the daughter infectious virus is reduced. Aminocaproic acid not only exhibits antiviral activity, but also improves some cellular and humoral indicators of specific and nonspecific body defense in respiratory viral infections.

Indications

Surgical operations and pathological processes, accompanied by an increase in fibrinolytic activity of blood and tissues.

To prevent secondary hypofibrinogenemia during massive transfusions of canned blood.

Contraindications

Thromboembolism, coagulopathy due to diffuse intravascular coagulation, renal failure, childbirth, cerebrovascular accident, a tendency to thrombosis, hematuria, severe coronary heart disease, hypersensitivity to drug components, a tendency to thromboembolic diseases, kidney disease with impaired function.

Directions

Aminocaproic acid 50 mg/ml. is used intravenously.

If it is necessary to achieve a quick effect (acute hypofibrinogenemia), adults should inject no more than 100 ml of a 5% solution by drip at a rate of 50-60 drops per minute for 15-30 minutes. During the first hour, administer 4-5 g, and in case of prolonged bleeding – until it stops completely – hourly 1 g, but not more than 8 g. In case of repeated bleeding, repeat the administration of the drug at intervals of 4 hours, but not more than 8 hours.

Children.
With a moderate increase in fibrinolytic activity, the drug “Aminocaproic acid-Darnitsa” is prescribed once at a dose of 0.05 g/kg of body weight per day. The dose, depending on age, is: for children under the age of 1 year: single – up to 2.5 ml, daily – 15 ml; at the age of 2 to 6 years: single – 2.5-5 ml, daily – 15-30 ml; from 7 to 10 years: single – 5-7 ml, daily – 30-45 ml; from 11 to 18 years: single – 7-14 ml, daily – 45-90 ml.
In case of acute bleeding, the doses are: for children under the age of 1 year: single – 5 ml, daily – 30 ml; at the age of 2 to 4 years: single – 5-7.5 ml, daily – 30-45 ml; from 5 to 8 years: single – 7.5-10 ml, daily – 45-60 ml; from 9 to 10 years: single – 15 ml, daily – 90 ml; from 11 to 14 years: single – 20 ml, daily – 120 ml; from 15 to 18 years: single – 28 ml, daily – 160 ml.

The course of treatment is from 3 to 14 days.

Related products